Efficacy and predictive markers of response to tofacitinib and baricitinib therapy in alopecia areata: A 52-week comparative cohort study

A 52-week prospective cohort study with 45 alopecia areata patients compared the efficacy of tofacitinib and baricitinib. Both drugs showed similar efficacy and safety, with median hair regrowth of 81.4% for tofacitinib and 100% for baricitinib. The study found no significant difference in achieving SALT30 or SALT ≤20% between the two treatments. However, baricitinib had a higher rate of early responders by week 12. Baseline disease severity was the only independent predictor of treatment response, emphasizing its importance in therapy planning. No serious adverse events were reported.